Editas Medicine (EDIT) Income from Non-Controlling Interests (2022 - 2025)
Editas Medicine's (EDIT) quarterly Income from Non-Controlling Interests came in at -$73000.0 in Q2 2025, up 37.07% year-on-year from -$53257.9 in Q2 2024, and up 59.44% on a QoQ basis from -$180000.0 in Q1 2025.
Editas Medicine (EDIT) Income from Non-Controlling Interests (2022 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 4 years of Income from Non-Controlling Interests data on file, last reported at -$73000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Editas Medicine | 245.95 Mn | 99.30 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -180,000.00 |
| Jun 30, 2024 | -116,000.00 |
| Mar 31, 2024 | -524,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | 1.32 Mn |
| Jun 30, 2022 | -878,000.00 |
| Mar 31, 2022 | -2.02 Mn |